Full View

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

E Raichlin, JH Bae, Z Khalpey, BS Edwards… - Circulation, 2007 - Am Heart Assoc
Background—We investigated the potential of conversion to sirolimus (SRL) as a primary
immunosuppressant in attenuating cardiac allograft vasculopathy progression. Methods and …
被引用次数：183 相关文章
[PDF] academia.edu

[PDF][PDF] Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation

E Raichlin, JH Bae, Z Khalpey, BS Edwards… - 2007 - academia.edu
Background—We investigated the potential of conversion to sirolimus (SRL) as a primary
immunosuppressant in attenuating cardiac allograft vasculopathy progression. Methods and …

[引用][C] Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation

E RAICHLIN, JH BAE, SS KUSHWAHA… - … (New York, NY), 2007 - pascal-francis.inist.fr
Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of
Allograft Vasculopathy After Cardiac Transplantation CNRS Inist Pascal-Francis CNRS …

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

E Raichlin, JH Bae, Z Khalpey, BS Edwards… - …, 2007 - experts.nebraska.edu
BACKGROUND: We investigated the potential of conversion to sirolimus (SRL) as a primary
immunosuppressant in attenuating cardiac allograft vasculopathy progression. METHODS …

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

E Raichlin, JH Bae, Z Khalpey, BS Edwards… - …, 2007 - mayoclinic.elsevierpure.com
BACKGROUND: We investigated the potential of conversion to sirolimus (SRL) as a primary
immunosuppressant in attenuating cardiac allograft vasculopathy progression. METHODS …

Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation

E Raichlin, JH Bae, Z Khalpey, BS Edwards… - Circulation, 2007 - cir.nii.ac.jp
抄録< jats: p>< jats: bold>< jats: italic> Background—</jats: italic></jats: bold> We
investigated the potential of conversion to sirolimus (SRL) as a primary immunosuppressant …

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

E Raichlin, JH Bae, Z Khalpey, BS Edwards… - …, 2007 - pubmed.ncbi.nlm.nih.gov
Background We investigated the potential of conversion to sirolimus (SRL) as a primary
immunosuppressant in attenuating cardiac allograft vasculopathy progression. Methods and …

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.

E Raichlin, JH Bae, Z Khalpey, BS Edwards… - Circulation, 2007 - europepmc.org
Background We investigated the potential of conversion to sirolimus (SRL) as a primary
immunosuppressant in attenuating cardiac allograft vasculopathy progression. Methods and …
[PDF] academia.edu

[PDF][PDF] Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation

E Raichlin, JH Bae, Z Khalpey, BS Edwards… - 2007 - academia.edu
Background—We investigated the potential of conversion to sirolimus (SRL) as a primary
immunosuppressant in attenuating cardiac allograft vasculopathy progression. Methods and …

[引用][C] Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation

E RAICHLIN, JH BAE, Z KHALPEY… - …, 2007 - Lippincott Williams & Wilkins